F2G develops novel therapeutics for rare fungal infections, focusing on effective antifungals to provide more options for patients.

F2G | 6,800 followers on LinkedIn. The rare fungal disease company | F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides have a distinct mechanism of action, selectively targeting fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway.

Biopharma C-suite Executive & Board Director┃ International P&L Management┃ Global Portfolio & Product Strategy, Commercialisation and Life Cycle…

Camilla Soenderby

Francesco Maria Lavino

Board Chair and Senior Advisor

Patrick Vink

CBO, F2G

Janelle R. Anderson

We're excited to present six posters at IDWeek 2024, showcasing our commitment to advancing novel antifungal treatments for invasive fungal infections! We look forward to connecting with peers in the #InfectiousDisease community to share insights and explore the latest advancements. See you at #IDWeek2024 🦠

As #FungalWeek24 concludes, revisit an insightful panel from last year’s #SXSW , featuring #InfectiousDisease experts from F2G, the Centers for Disease Control and Prevention , and academia, that highlights the challenges of fungal diseases, treatment complexities, and cross-resistance. Fungal infections are a growing global health issue. Watch the full panel to gain valuable insights on how we’re collectively hoping to address these challenges and advance the future of antifungal treatments: https://bit.ly/3MmYtSo

At F2G, we understand that the fight against fungal diseases requires more than just treatment innovation, it demands a comprehensive approach that considers the connection between human, animal, and environmental health. The "One Health" approach highlights the reality that fungal infections often stem from interactions within our ecosystems. By recognizing these links, we can better address the root causes of fungal diseases and advance more effective, sustainable treatments. This #FungalWeek24 , learn more from the Centers for Disease Control and Prevention about how fungal diseases are a One Health issue: https://bit.ly/3Z2lxNJ

Fungal diseases and antimicrobial resistance are on the rise globally, yet there has been limited treatment innovation to address these pressing challenges. This #FungalWeek24 , join us in raising awareness and education on these critical issues in the space. Learn more from the Centers for Disease Control and Prevention : https://bit.ly/3Z2lxNJ

We are thrilled to announce the close of a $100 million financing round, led by new investor AMR Action Fund with strong participation from new investor Intermediate Capital Group (ICG) Life Sciences and existing investors. The funds will be used to advance the late-stage development and commercialization of our novel antifungal drug candidate in the US. Read our new press with financing details on the media section of the F2G corporate website: https://bit.ly/3UlKDVE

At #SXSW2024 , our Chief Medical Officer, Dr. John Rex, joined a panel of infectious disease experts from government and academia to discuss the increasing threat of fungal infections, the effects of climate change, and addressing the global challenge. Read more in the Washington Examiner: https://bit.ly/3IyyuWd #FungiForumSXSW SXSW

We are proud to sponsor the 68th Annual Coccidioidomycosis Study Group because we believe in the power of knowledge exchange to drive innovation in the prevention and treatment of invasive fungal infections like Coccidioidomycosis (valley fever). We’ll share data through two oral presentations and a poster highlighting the progress being made by our team and partners. To learn more about what we are doing to address valley fever, visit: https://bit.ly/3THVE1h

Attending #SXSW2024 ? Our Chief Medical Officer, Dr. John Rex, will join a dynamic panel of fungal disease experts on Monday, March 11 at 4pm CST in Austin, TX. Don’t miss out on this engaging discussion—add it to your calendar now! https://brnw.ch/21wHHVN @sxsw #FungiForumSXSW

Attending #SXSW2024 ? Our Chief Medical Officer, Dr. John Rex, will join a dynamic panel of fungal disease experts on Monday, March 11 at 4pm CST in Austin, TX. Don’t miss out on this engaging discussion—add it to your calendar now! https://brnw.ch/21wHHsP @sxsw #FungiForumSXSW

Join us at #SXSW2024 on Monday, March 11 at 4pm CST, where a panel of infectious disease experts from F2G, government, and academia will explore challenges posed by fungi, treatment complexities, cross-resistance, and shared DNA hurdles in antifungal development. Learn more: https://brnw.ch/21wHF4y #FungiForumSXSW

Retro Run

onsenvole

CastleQuiz

Step trackin

Castlecross

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Euro

Apple Mobile Web Clips Icon

Google Font API

HSTS

Content Delivery Network

WordPress

Vice President, Technical Operations & Supply Chain

Marcelo Omelczuk

Corporate Account Director

Adriana Sanchez

Finance and Administration

Belinda Lovelace

Dave Villegas

Director Early Clinical Development

Karen Cornelissen

Senior Director, US Medical Affairs

Lisa DiPompo

Executive Director, Clinical R&D

Mark Bresnik

Operations

Ricardo (Rick) Arce, MSc.

Director, Data Management

Sandra Thorn

Global Head of Information Technology

Sean B. Cuttler

Nanna Lüneborg

Naveed Siddiqi

Eric Richman

Joe Anderson

Richard White

Maha Katabi

George Drusano

Martin Edwards

Ian Nicholson

Chief Executive Officer

Tony Kennedy

Chief Scientific and Development Officer

Mike Birch

Chief Operating Officer

Christopher Wright

Non Executive Director

Raj Parekh

Janelle Anderson

Chief Business Officer

John H. Rex

Chief Medical Officer

Ralf Schmid

City of Manchester Companies With Fewer Than 1000 Employees

Biotechnology Late Stage Companies With Fewer Than 100 Employees

Forbion Capital Partners Portfolio Companies

Europe, Middle East, and Africa (EMEA) Companies (Top 10K)

F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBankÂ®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.

AMR Action Fund

Intermediate Capital Group

Series H - F2G

Forbion Capital Partners

Sofinnova Partners

Private Equity Round - F2G

Cowen Healthcare Investments

European Investment Bank

Debt Financing - F2G

Sectoral Asset Management

Innovate UK

Grant - F2G

Novartis Venture Fund

Venture Round - F2G

BankInvest Biomedical Venture

Astellas Venture Management

Manchester

United Kingdom

Europe

Armed with $100m funding, F2G prepares to refile antifungal

Fungal Pneumonia Market to Witness Growth by 2032, Estimates DelveInsight | Companies involved: Pfizer, Merck ...

FDA stalls F2G's plans to get first in new antifungal class to market

F2G receives a CRL and a request for more data for its antifungal

FDA declines to approve Shionogi, F2G's antifungal olorofim

F2G Ltd–Advent Life Sciences: investment, 202208 financing round totalling $70m inc existing + co-investor Advent Life Sciences

Forbion Co-leads $70 Million Financing of F2G to Advance Development and Commercialization of New Antifungal Agent Olorofim

Funding: Pharmaceutical Startup F2G Raised $70 million

Philippines

Asia

The Netherlands

India

HTML5

Symantec Email Security.Cloud

Office 365

Adobe Flash

Apache Server

Google Drive

Google Maps API

Bootstrap

Amazon EC2

F5 NGINX

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 6, 2024 11:28 PM	894268d9
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 6, 2024 11:28 PM	ecce4af3
crunchbase trigger	general	Nov 6, 2024 11:28 PM	403c9999
crunchbase profile	general	Nov 7, 2024 10:27 PM	fc700779
li profile	general	Nov 6, 2024 11:28 PM	b0688ddd
translate crunchbase fundingrounds	general	Nov 7, 2024 11:03 PM	dd29ad10
peers	general	Nov 6, 2024 11:28 PM	a5a7cfc2
news basic	general	Nov 6, 2024 11:28 PM	94a383e9
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

F2G

COM:F2G

F2G